Clinical implications of human leukocyte antigen class I expression in endometrial cancer

Yakabe,Kazuyuki; Murakami,Akihiro; Nishimoto,Yuki; Kajimura,Takuya; Sueoka,Kotaro; Sugino,Norihiro

doi:10.3892/mco.2015.636

Clinical implications of human leukocyte antigen class I expression in endometrial cancer

Authors:
- Kazuyuki Yakabe
- Akihiro Murakami
- Yuki Nishimoto
- Takuya Kajimura
- Kotaro Sueoka
- Norihiro Sugino
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi 755-8505, Japan
Published online on: September 3, 2015 https://doi.org/10.3892/mco.2015.636
Pages: 1285-1290

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Decreased expression of human leukocyte antigen (HLA) class I molecules, which is found in several types of cancer, is associated with worse clinical prognosis in cancer patients. The present study was undertaken to investigate the association of immunohistochemical HLA class I expression patterns with clinicopathological factors and prognosis in 96 endometrial cancer patients. HLA class I is composed of a heavy chain (HC-10) and a β2-microglobulin (β2-m) light chain. The HLA class I expression patterns were classified as positive when both HC-10 and β2-m were strongly stained and negative in all other cases. The negative staining pattern was associated with advanced International Federation of Gynecology and Obstetrics stage (p<0.001), lymphovascular space involvement (LVSI) (p=0.003) and lymph node metastasis (p=0.005). Moreover, these cases exhibited worse progression‑free survival (PFS) and overall survival (OS) rates compared with positive cases (p=0.005 and p=0.014, respectively). However, the multivariate analysis did not identify HLA class I expression as an independent predictive factor for PFS and OS. In conclusion, HLA class I expression may be useful for predicting postoperative outcome in endometrial cancer, as well as well-known predictive prognostic factors, such as lymph node metastasis and LVSI.

View Figures

View References

1	Garrido F, Ruiz-Cabello F, Cabrera T, Pérez-Villar JJ, López-Botet M, Duggan-Keen M and Stern PL: Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today. 18:89–95. 1997. View Article : Google Scholar : PubMed/NCBI
2	Hicklin DJ, Marincola FM and Ferrone S: HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today. 5:178–186. 1999. View Article : Google Scholar : PubMed/NCBI
3	Gabrilovich D and Pisarev V: Tumor escape from immune response: Mechanisms and targets of activity. Curr Drug Targets. 4:525–536. 2003. View Article : Google Scholar : PubMed/NCBI
4	Rolland P, Deen S, Scott I, Durrant L and Spendlove I: Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer. Clin Cancer Res. 13:3591–3596. 2007. View Article : Google Scholar : PubMed/NCBI
5	Mehta AM, Jordanova ES, Kenter GG, Ferrone S and Fleuren GJ: Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother. 57:197–206. 2008. View Article : Google Scholar : PubMed/NCBI
6	Speetjens FM, de Bruin EC, Morreau H, et al: Clinical impact of HLA class I expression in rectal cancer. Cancer Immunol Immunother. 57:601–609. 2008. View Article : Google Scholar : PubMed/NCBI
7	Ueda Y, Ishikawa K, Shiraishi N, Yokoyama S and Kitano S: Clinical significance of HLA class I heavy chain expression in patients with gastric cancer. J Surg Oncol. 97:451–455. 2008. View Article : Google Scholar : PubMed/NCBI
8	Mizukami Y, Kono K, Maruyama T, Watanabe M, Kawaguchi Y, Kamimura K and Fujii H: Downregulation of HLA class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. Br J Cancer. 99:1462–1467. 2008. View Article : Google Scholar : PubMed/NCBI
9	Kikuchi E, Yamazaki K, Torigoe T, Cho Y, Miyamoto M, Oizumi S, Hommura F, Dosaka-Akita H and Nishimura M: HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci. 98:1424–1430. 2007. View Article : Google Scholar : PubMed/NCBI
10	Bijen CB, Bantema-Joppe EJ, de Jong RA, Leffers N, Mourits MJ, Eggink HF, van der Zee AG, Hollema H, de Bock GH and Nijman HW: The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer. Int J Cancer. 126:1417–1427. 2010.PubMed/NCBI
11	Kaneko K, Ishigami S, Kijima Y, et al: Clinical implication of HLA class I expression in breast cancer. BMC Cancer. 11:4542011. View Article : Google Scholar : PubMed/NCBI
12	Barrier BF, Kendall BS, Sharpe-Timms KL and Kost ER: Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma. Gynecol Oncol. 103:25–30. 2006. View Article : Google Scholar : PubMed/NCBI
13	de Jong RA, Boerma A, Boezen HM, Mourits MJ, Hollema H and Nijman HW: Loss of HLA class I and mismatch repair protein expression in sporadic endometrioid endometrial carcinomas. Int J Cancer. 131:1828–1836. 2012. View Article : Google Scholar : PubMed/NCBI
14	Murakami A, Fukushima C, Yoshidomi K, Sueoka K, Nawata S, Yokoyama Y, Tsuchida S, Ismail E, Al-Mulla F and Sugino N: Suppression of carbonyl reductase expression enhances malignant behaviour in uterine cervical squamous cell carcinoma: Carbonyl reductase predicts prognosis and lymph node metastasis. Cancer Lett. 311:77–84. 2011. View Article : Google Scholar : PubMed/NCBI
15	Torigoe T, Asanuma H, Nakazawa E, Tamura Y, Hirohashi Y, Yamamoto E, Kanaseki T, Hasegawa T and Sato N: Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: Unusually high frequency of down-regulation in breast cancer tissues. Pathol Int. 62:303–308. 2012. View Article : Google Scholar : PubMed/NCBI
16	Murakami A, Yakabe K, Yoshidomi K, Sueoka K, Nawata S, Yokoyama Y, Tsuchida S, Al-Mulla F and Sugino N: Decreased carbonyl reductase 1 expression promotes malignant behaviours by induction of epithelial mesenchymal transition and its clinical significance. Cancer Lett. 323:69–76. 2012. View Article : Google Scholar : PubMed/NCBI
17	Seliger B: Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother. 57:1719–1726. 2008. View Article : Google Scholar : PubMed/NCBI
18	Kondratiev S, Sabo E, Yakirevich E, Lavie O and Resnick MB: Intratumoral CD8+ Tlymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res. 10:4450–4456. 2004. View Article : Google Scholar : PubMed/NCBI
19	Ino K, Yamamoto E, Shibata K, Kajiyama H, Yoshida N, Terauchi M, Nawa A, Nagasaka T, Takikawa O and Kikkawa F: Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: Its association with disease progression and survival. Clin Cancer Res. 14:2310–2317. 2008. View Article : Google Scholar : PubMed/NCBI